SRSF6 Regulates the Alternative Splicing of the Apoptotic Fas Gene by Targeting a Novel RNA Sequence
Overview
Authors
Affiliations
Alternative splicing (AS) is a procedure during gene expression that allows the production of multiple mRNAs from a single gene, leading to a larger number of proteins with various functions. The alternative splicing (AS) of Fas (Apo-1/CD95) pre-mRNA can generate membrane-bound or soluble isoforms with pro-apoptotic and anti-apoptotic functions. SRSF6, a member of the Serine/Arginine-rich protein family, plays essential roles in both constitutive and alternative splicing. Here, we identified SRSF6 as an important regulatory protein in Fas AS. The cassette exon inclusion of Fas was decreased by SRSF6-targeting shRNA treatment, but increased by SRSF6 overexpression. The deletion and substitution mutagenesis of the Fas minigene demonstrated that the UGCCAA sequence in the cassette exon of the Fas gene causes the functional disruption of SRSF6, indicating that these sequences are essential for SRSF6 function in Fas splicing. In addition, biotin-labeled RNA-pulldown and immunoblotting analysis showed that SRSF6 interacted with these RNA sequences. Mutagenesis in the splice-site strength alteration demonstrated that the 5' splice-site, but not the 3' splice-site, was required for the SRSF6 regulation of Fas pre-mRNA. In addition, a large-scale RNA-seq analysis using GTEX and TCGA indicated that while SRSF6 expression was correlated with Fas expression in normal tissues, the correlation was disrupted in tumors. Furthermore, high SRSF6 expression was linked to the high expression of pro-apoptotic and immune activation genes. Therefore, we identified a novel RNA target with 5' splice-site dependence of SRSF6 in Fas pre-mRNA splicing, and a correlation between SRSF6 and Fas expression.
Targeting RNA splicing modulation: new perspectives for anticancer strategy?.
Lv X, Sun X, Gao Y, Song X, Hu X, Gong L J Exp Clin Cancer Res. 2025; 44(1):32.
PMID: 39885614 PMC: 11781073. DOI: 10.1186/s13046-025-03279-w.
Tzaban S, Stern O, Zisman E, Eisenberg G, Klein S, Frankenburg S Front Immunol. 2025; 15():1490035.
PMID: 39845971 PMC: 11752881. DOI: 10.3389/fimmu.2024.1490035.
Biological relevance of alternative splicing in hematologic malignancies.
Szelest M, Giannopoulos K Mol Med. 2024; 30(1):62.
PMID: 38760666 PMC: 11100220. DOI: 10.1186/s10020-024-00839-2.
Role of RNA Alternative Splicing in T Cell Function and Disease.
Banerjee S, Galarza-Munoz G, Garcia-Blanco M Genes (Basel). 2023; 14(10).
PMID: 37895245 PMC: 10606310. DOI: 10.3390/genes14101896.
Towards understandings of serine/arginine-rich splicing factors.
Li D, Yu W, Lai M Acta Pharm Sin B. 2023; 13(8):3181-3207.
PMID: 37655328 PMC: 10465970. DOI: 10.1016/j.apsb.2023.05.022.